Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 327
- Registration Number
- NCT03671330
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Tianjin, China
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
- Conditions
- Moderate to Severe Chronic Plaque-type Psoriasis
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 84
- Registration Number
- NCT03668613
- Locations
- ๐บ๐ธ
Texas Derm and Laser Specialists ., San Antonio, Texas, United States
๐บ๐ธFirst OC Dermatology, Fountain Valley, California, United States
๐ช๐ธNovartis Investigative Site, Valencia, Spain
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
- Conditions
- Kidney Transplant Rejection
- Interventions
- Drug: Tacrolimus - MMF - +/- corticosteroidsBiological: CFZ533 - MMF - CS
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 418
- Registration Number
- NCT03663335
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Manchester, United Kingdom
Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: VAY736Drug: CFZ533Drug: VAY736 PlaceboDrug: CFZ533 Placebo
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 107
- Registration Number
- NCT03656562
- Locations
- ๐น๐ญ
Novartis Investigative Site, Bangkok, Thailand
Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT03650400
- Locations
- ๐บ๐ธ
Novartis Investigative Site, San Antonio, Texas, United States
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Biological: OfatumumabBiological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)Biological: 13-valent pneumococcal conjugate vaccine (13-PCV)Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)Biological: Seasonal Quadrivalent influenza vaccineBiological: Keyhole limpet hemocyanin (KLH) neo-antigen
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2060
- Registration Number
- NCT03650114
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธNorth Central Neurology Associates PC, Cullman, Alabama, United States
๐บ๐ธBarrow Neurological Clinics at St Josephs Hospital and MC, Phoenix, Arizona, United States
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03647488
- Locations
- ๐บ๐ธ
Highlands Oncology Group, Fayetteville, Arkansas, United States
๐ช๐ธNovartis Investigative Site, Madrid, Spain
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: canakinumabDrug: canakinumab-matching placeboDrug: pembrolizumabDrug: carboplatinDrug: cisplatinDrug: pemetrexedDrug: paclitaxelDrug: nab-paclitaxel
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 673
- Registration Number
- NCT03631199
- Locations
- ๐บ๐ธ
Pacific Shores Medical Group ., Long Beach, California, United States
๐บ๐ธUSC Kenneth Norris Comprehensive Cancer Center ., Los Angeles, California, United States
๐บ๐ธAdvent Health Cancer Institute, Orlando, Florida, United States
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03628053
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Biological: TisagenlecleucelDrug: Pembrolizumab
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT03630159
- Locations
- ๐บ๐ธ
Emory University School of Medicine SC CTL019, Atlanta, Georgia, United States
๐บ๐ธUniversity of Kansas Hospital and Medical Center U of Kansas Cancer Center, Kansas City, Kansas, United States
๐บ๐ธUniversity of Chicago Medical Center Hematology and Oncology, Chicago, Illinois, United States